1760 Stock Overview
A biotechnology pharmaceutical company, manufactures, distributes, and trades in western medicines, cosmetics, testing reagents, food products, and chemicals in Taiwan, the United States, China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Panion & Bf Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$89.50 |
| 52 Week High | NT$125.50 |
| 52 Week Low | NT$76.20 |
| Beta | 0.23 |
| 11 Month Change | 4.07% |
| 3 Month Change | -5.29% |
| 1 Year Change | -21.15% |
| 33 Year Change | 27.86% |
| 5 Year Change | -0.78% |
| Change since IPO | 690.24% |
Recent News & Updates
Recent updates
Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?
Aug 13
Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden
Apr 07Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?
Mar 03Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years
Feb 04
Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?
Jan 09Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet
Dec 14Shareholder Returns
| 1760 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.2% | 0.6% | -0.8% |
| 1Y | -21.1% | 9.2% | 29.0% |
Return vs Industry: 1760 underperformed the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 1760 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 1760 volatility | |
|---|---|
| 1760 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1760 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1760's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | n/a | Tsung-Ming Chiang | www.pbf.com.tw |
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures, distributes, and trades in western medicines, cosmetics, testing reagents, food products, and chemicals in Taiwan, the United States, China, Hong Kong, and internationally. The company offers products in the areas of personal cleaning, medical aesthetic, kidney-specific, pet care, and delay aging, as well as disease treatment, prevention, and diagnosis. It provides body cleansing, emollient lotion, hair cleansing, in-hospital care, minimally invasive, frozen age care and maintenance, oral medication, skin and hand disinfection, respiratory and gastrointestinal tract, and salon products; and pet health products, including surgical and skin prescriptions.
Panion & Bf Biotech Inc. Fundamentals Summary
| 1760 fundamental statistics | |
|---|---|
| Market cap | NT$7.63b |
| Earnings (TTM) | NT$121.33m |
| Revenue (TTM) | NT$2.04b |
63.2x
P/E Ratio3.8x
P/S RatioIs 1760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1760 income statement (TTM) | |
|---|---|
| Revenue | NT$2.04b |
| Cost of Revenue | NT$968.40m |
| Gross Profit | NT$1.07b |
| Other Expenses | NT$946.04m |
| Earnings | NT$121.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 52.43% |
| Net Profit Margin | 5.96% |
| Debt/Equity Ratio | 33.9% |
How did 1760 perform over the long term?
See historical performance and comparison